Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan

British Journal of Pharmacology

Volumn 134, Issue 7, 2001, Pages 1385-1392

  Katugampola, S D ^a   Davenport, A P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiotensin; Atherosclerosis; Cardiomyopathy; Human coronary artery; Human heart; Losartan; Pulmonary hypertension; Saphenous vein graft; Thromboxane; Thromboxane receptor

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HEPTANOIC ACID DERIVATIVE; LOSARTAN; PROSTACYCLIN; PROSTAGLANDIN E2; RADIOLIGAND; THROMBOXANE; THROMBOXANE RECEPTOR; UK 147 535; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BINDING COMPETITION; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HEART LEFT VENTRICLE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; SAPHENOUS VEIN GRAFT;

EID: 0035214283     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704416     Document Type: Article

References (48)

1. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers
2. Coupling of thromboxane A2 receptor isoforms to Galpha 13: Effects on ligand binding and signalling
3. Characterisation of thromboxane A2/prostaglandin H2 binding sites in guinea pig cardiac membrane preparations
4. Thromboxane receptors in human kidney tissue
5. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
6. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
7. Thromboxane modulating agents. 4. Design and synthesis of 3-(2 - [[(4 - chlorophenyl)sulfonyl] - amino]ethyl) benzenepropanoic acid derivatives as potent thromboxane receptor antagonists
8. A sub-type
9. A selective non-peptide radiolabelled antagonist, in normal and diseased human tissue
10. Idiopathic dilated cardiomyopathy
11. Tissue and species-specific differences in ligand binding to thromboxane A2 receptors
12. 2 concentrations in pulmonary hypertension associated with congenital heart disease
13. Thromboxane synthase inhibitors, thromboxane receptor antagonist and dual blockers in thrombotic disorders
14. Effect of losartan on human platelet activation
15. 2 in health and disease
16. Thromboxane, prostaglandin and leukotriene receptors
17. 2 receptor
18. Angiotensin II can induce and potentiate shape change in platelets: Effect of losartan
19. The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis
20. Human internal mammary artery possesses a greater density of thromboxane A2 receptors than the coronary artery: Differential distribution in human vasculature
21. Distribution of thromboxane receptors in the normal human heart and its alteration with disease
22. 2 receptors on human endothelial cells
23. Inhibition of platelet aggregability by losartan in essential hypertension
24. 2 induced contractions in canine coronary arteries
25. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endotehlin-1, to distinguish between these agonists in binding experiments
26. Endothelin receptor expression and pharmacology in human saphenous vein grafts
27. A practical computer-based approach to the analysis of radioligand binding experiments
28. Human vascular tissues produce thromboxane as well as prostacyclin
29. Prostacyclin and thromboxane A2 production by human cardiac atrial tissues
30. Increased prostacyclin and thromboxane biosynthesis in atherosclerosis
31. 125I-labeled thromboxane A2/ prostaglandin H2 receptor agonist
32. Characterisation of thromboxane A2/ prostaglandin H2 receptors in human vascular smooth muscle cells
33. 2-stimulated mitogenesis of coronary artery smooth muscle cells involves activation of mitogen-activated protein kinase and S6 kinase
34. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
35. LIGAND: A versatile computerised approach for the characterisation of ligand binding systems
36. Prostanoid receptors: Structure, properties and functions
37. Characterisation and chromosomal mapping of the human thromboxane A2 receptor gene
38. Interspecies differences in thromboxane receptors-studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles
39. Cellular activation by thromboxane A2 and other eicosanoids
40. 2 and vascular smooth muscle cell proliferation
41. Positive inotropic effect of the thromboxane analogue U-46619 on guinea pig left atrium: Mediation by specific receptors and association with increased phosphoinositide turnover
42. 2 production in patients with ischemic heart disease: Relationships to coronary pathoanatomy, risk factors and clinical manifestations
43. 2 production by human arteries and veins
44. Pharmacology of thromboxane synthetase inhibitors
45. Excellent outcome of cardiac transplantation using domino donor hearts
46. Endothelial thromboxane receptors: Biochemical characterisation and functional implications
47. Cardiac release of prostacyclin and thromboxane A2 during coronary revascularisation
48. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent